Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial - Camu, William; Mickunas, Marius; Veyrune, Jean-Luc; Payan, Christine; Garlanda, Cecilia; Locati, Massimo; Juntas-Morales, Raul; Pageot, Nicolas; Malaspina, Andrea; Andreasson, Ulf; Kirby, Janine; Suehs, Carey; et al. (EBioMedicine, 2020)
Keywords: Advanced Basic Science; Aged; Aged, 80 and over; Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - diagnosis; Amyotrophic Lateral Sclerosis - drug therapy; Amyotrophic Lateral Sclerosis - etiology; Amyotrophic Lateral Sclerosis - metabolism; Antineoplastic Agents - administration & dosage; Biomarkers; Chemokines; Cytokines; Female; Humans; Immunology; Immunophenotyping; Interleukin-2 - administration & dosage; Interleukin-2 - analogs & derivatives; Interleukin-2 - metabolism; Internal Medicine; Life Sciences; Low dose interleukin-2; Male; Middle Aged; Neuro-inflammation; Neurosciences; Neurovetenskaper; Randomised clinical trial; Recombinant Proteins - administration & dosage; Regulatory T cells; Research Paper; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - metabolism; Treatment Outcome; Biomarkers; Amyotrophic lateral sclerosis; Neuro-inflammation; Regulatory T cells; Randomised clinical trial; Low dose interleukin-2; Amyotrophic lateral Sclerosis